3 Results for "

CX3CR1/CX3CL1

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CX3CR1/CX3CL1" in MCE Product Catalog:

Cat. No.: HY-175746
CAS No.: 3036141-78-0
Target:  

CX3CR1

Research Areas:  

Cardiovascular Disease

AZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research .
loading...
    loading...
Cat. No.: HY-P99404
CAS No.: 2084037-83-0
Synonyms: E6011

Target:  

CXCR

Research Areas:  

Inflammation/Immunology Cancer

Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
loading...
    loading...
Cat. No.: HY-181016
CAS No.: 3105688-14-7
Target:  

CX3CR1

Research Areas:  

Cardiovascular Disease

CX3CR1-IN-2 (Compound 77) is a CX3CR1 inhibitor with an IC50 of 0.04 μM. CX3CR1-IN-2 can block the interaction between CX3CR1 and its ligand fractalkine (CX3CL1). CX3CR1-IN-2 can be used for research of cardiovascular disease, such as heart failure and cardiomyopathy .
loading...
    loading...